Human fetal midbrain tissue grafting has provided proof-of-concept for dopamine cell replacement therapy (CRT) in Parkinson's disease (PD). However, limited tissue availability has hindered the development and widespread use of this experimental therapy. Here we present a method for generating large numbers of midbrain dopaminergic (DA) neurons based on expanding and differentiating neural stem/progenitor cells present in the human ventral midbrain (hVM) tissue. Our results show that hVM neurospheres (hVMN) with low cell numbers, unlike their rodent counterparts, expand the total number of cells 3-fold, whilst retaining their capacity to differentiate into midbrain DA neurons. Moreover, Wnt5a promoted DA differentiation of expanded cells resulting in improved morphological maturation, midbrain DA marker expression, DA release and electrophysiological properties. This method results in cell preparations that, after expansion and differentiation, can contain 6-fold more midbrain DA neurons than the starting VM preparation. Thus, our results provide evidence that by improving expansion and differentiation of progenitors present in the hVM it is possible to greatly enrich cell preparations for DA neurons. This method could substantially reduce the amount of human fetal midbrain tissue necessary for CRT in patients with PD, which could have major implications for the widespread adoption of this approach.
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Introduction
Parkinson's disease (PD) is a neurodegenerative disorder characterized by resting tremor, rigidity and slowness of movement (hypokinesia). The motor features of PD are due in part to the progressive loss of dopaminergic (DA) neurons in the substantia nigra pars compacta (SNpc), which project to the striatum and are involved in motor control. One promising therapeutic approach is cell-replacement therapy (CRT), in which DA neurons and/or precursors are grafted into the striatum in order to restore the lost nigrostriatal DA neurotransmission. Several cell types have been considered as potential sources of DA neurons, such as embryonic stem (ES) cells and induced pluripotent stem (iPS) cells which, due to their capacity to expand and differentiate, can generate large numbers of DA neurons and induce behavioral improvement in animal models of PD (Barberi et al., 2003; Hargus et al., 2010; Kawasaki et al., 2000; Kim et al., 2002; Kriks et al., 2011; Lee et al., 2000; Sanchez-Pernaute et al., 2008; Wernig et al., 2008) . However, the lack of purity of the differentiated cultures, the risk of excessive proliferation and teratoma formation, as well as the poor survival of human ES cell-
